Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.
ESMO World Congress on Gastrointestinal Cancer 2015
A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.
Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.
A new study has found that in patients diagnosed with metastatic colorectal cancer, a low BMI could be a poor prognostic factor.
Adding the oral NK1 antagonist aprepitant to an oxaliplatin-based chemotherapy regimen effectively reduced nausea and vomiting in colorectal cancer patients.
Ahead of the ESMO World Congress on Gastrointestinal Cancer, we are discussing the use of maintenance therapy in metastatic colorectal cancer with Axel Grothey, MD.